X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6601) 6601
Publication (623) 623
Newsletter (210) 210
Book Review (159) 159
Book Chapter (26) 26
Newspaper Article (24) 24
Magazine Article (16) 16
Dissertation (14) 14
Conference Proceeding (9) 9
Trade Publication Article (3) 3
Data Set (2) 2
Government Document (2) 2
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
zoledronic acid (6338) 6338
humans (3674) 3674
index medicus (3253) 3253
female (2021) 2021
bisphosphonates (1973) 1973
oncology (1857) 1857
male (1680) 1680
osteoporosis (1604) 1604
diphosphonates - therapeutic use (1457) 1457
bone density conservation agents - therapeutic use (1169) 1169
cancer (1137) 1137
aged (1102) 1102
middle aged (1087) 1087
bone neoplasms - secondary (1013) 1013
animals (1001) 1001
care and treatment (903) 903
metastasis (902) 902
postmenopausal women (865) 865
breast cancer (835) 835
bone metastases (822) 822
double-blind (811) 811
endocrinology & metabolism (787) 787
research (776) 776
denosumab (758) 758
risk factors (748) 748
diphosphonates - administration & dosage (744) 744
diphosphonates - pharmacology (742) 742
breast-cancer (731) 731
imidazoles - therapeutic use (730) 730
bones (725) 725
diphosphonates - adverse effects (725) 725
bisphosphonate (709) 709
bone neoplasms - drug therapy (705) 705
prostate cancer (678) 678
drug therapy (668) 668
fractures (647) 647
medicine & public health (639) 639
bone density conservation agents - adverse effects (610) 610
orthopedics (601) 601
alendronate (584) 584
bone (580) 580
analysis (578) 578
health aspects (578) 578
therapy (571) 571
bone density conservation agents - administration & dosage (568) 568
treatment outcome (567) 567
aged, 80 and over (545) 545
adult (541) 541
pamidronate (533) 533
bone-mineral density (523) 523
in-vitro (517) 517
multiple-myeloma (504) 504
imidazoles - pharmacology (492) 492
pharmacology & pharmacy (491) 491
prostate-cancer (479) 479
imidazoles - administration & dosage (474) 474
breast neoplasms - pathology (468) 468
prevention (462) 462
osteoporosis - drug therapy (446) 446
osteonecrosis (443) 443
breast neoplasms - drug therapy (442) 442
metastases (441) 441
chemotherapy (427) 427
bone density conservation agents - pharmacology (422) 422
phosphonates (414) 414
skeletal complications (414) 414
mice (400) 400
women (395) 395
bone density - drug effects (392) 392
diphosphonates (391) 391
skeletal-related events (387) 387
complications and side effects (386) 386
apoptosis (384) 384
surgery (379) 379
placebo-controlled trial (370) 370
antineoplastic agents - therapeutic use (365) 365
necrosis (362) 362
postmenopausal osteoporosis (358) 358
risk (358) 358
bone metastasis (355) 355
prostatic neoplasms - pathology (355) 355
dosage and administration (348) 348
survival (347) 347
dentistry, oral surgery & medicine (343) 343
imidazoles - adverse effects (343) 343
risk-factors (337) 337
medicine, general & internal (330) 330
bone density (328) 328
rheumatology (327) 327
multiple myeloma (324) 324
cell line, tumor (322) 322
dentistry (311) 311
prostatic neoplasms - drug therapy (310) 310
article (307) 307
bone mineral density (299) 299
density (294) 294
retrospective studies (292) 292
randomized controlled-trial (290) 290
hematology, oncology and palliative medicine (287) 287
pain (286) 286
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6584) 6584
German (79) 79
Spanish (63) 63
French (55) 55
Turkish (19) 19
Japanese (16) 16
Portuguese (15) 15
Chinese (14) 14
Russian (14) 14
Polish (10) 10
Korean (7) 7
Hungarian (5) 5
Italian (4) 4
Czech (2) 2
Arabic (1) 1
Croatian (1) 1
Estonian (1) 1
Persian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 1989 - 1999
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2011, Volume 365, Issue 15, pp. 1396 - 1405
Journal Article
Journal Article
BMC Musculoskeletal Disorders, ISSN 1471-2474, 07/2018, Volume 19, Issue 1, pp. 217 - 12
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Journal Article
Osteoporosis International, ISSN 0937-941X, 5/2018, Volume 29, Issue 5, pp. 1155 - 1163
Annual intravenous administration of zoledronic acid is used in the treatment of osteoporosis. A mathematical model was developed to predict bone mineral... 
Osteoporosis | Modeling and simulation | Tartrate-resistant acid phosphatase 5b (TRACP-5b) | Medicine & Public Health | Orthopedics | Bone resorption marker | Rheumatology | Zoledronic acid | Bone mineral density | Endocrinology | HOMEOSTASIS | DENOSUMAB | PREVENTION | PHARMACODYNAMICS | TERIPARATIDE | TRIAL | THERAPY | ENDOCRINOLOGY & METABOLISM | BMD | POSTMENOPAUSAL WOMEN | Bone Resorption - diagnosis | Bone Resorption - physiopathology | Zoledronic Acid - pharmacology | Double-Blind Method | Drug Administration Schedule | Zoledronic Acid - therapeutic use | Tartrate-Resistant Acid Phosphatase - blood | Humans | Bone Resorption - drug therapy | Bone Density Conservation Agents - therapeutic use | Male | Osteoporosis - drug therapy | Biomarkers - blood | Bone Density Conservation Agents - administration & dosage | Zoledronic Acid - administration & dosage | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Models, Biological | Aged, 80 and over | Female | Aged | Infusions, Intravenous | Osteoporosis - physiopathology | Lumbar Vertebrae - physiopathology | Bone resorption | Physiological aspects | Development and progression | Bones | Models | Drug therapy | Acid phosphatase | Health aspects | Density | Intravenous administration | Spine (lumbar) | Phosphatase | Patients | Fractures | Acids | Mathematical models | Acid phosphatase (tartrate-resistant) | Bone density | Original
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2009, Volume 360, Issue 7, pp. 679 - 691
This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment (goserelin plus tamoxifen or anastrozole) in premenopausal women... 
RECEIVING ADJUVANT LETROZOLE | MULTIPLE-MYELOMA | OVARIAN ABLATION | BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | DELTA-T-CELLS | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 6/2011, Volume 127, Issue 2, pp. 429 - 438
The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant... 
Medicine & Public Health | Osteonecrosis of the jaw | Zoledronic acid | Oncology | Breast cancer | Safety | Adjuvant therapy | BISPHOSPHONATE-ASSOCIATE